These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18728023)

  • 21. [The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
    Shen HJ; He J; Qiu QC; Cen JN; Pan JL; Yao L; Ding ZX; Chen Y; Chen ZX
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):21-5. PubMed ID: 23597459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
    Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
    Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
    Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
    De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
    Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.
    Hawkins LM; Jayanthan AA; Narendran A
    Pediatr Res; 2005 Mar; 57(3):430-7. PubMed ID: 15659698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
    Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
    Duncan EA; Goetz CA; Stein SJ; Mayo KJ; Skaggs BJ; Ziegelbauer K; Sawyers CL; Baldwin AS
    Mol Cancer Ther; 2008 Feb; 7(2):391-7. PubMed ID: 18245668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
    La Rosée P; Holm-Eriksen S; Konig H; Härtel N; Ernst T; Debatin J; Mueller MC; Erben P; Binckebanck A; Wunderle L; Shou Y; Dugan M; Hehlmann R; Ottmann OG; Hochhaus A
    Haematologica; 2008 May; 93(5):765-9. PubMed ID: 18367481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Research on resistance to cancer drug Gleevec.
    Sawyers CL
    Science; 2001 Nov; 294(5548):1834. PubMed ID: 11732550
    [No Abstract]   [Full Text] [Related]  

  • 31. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
    Griswold IJ; MacPartlin M; Bumm T; Goss VL; O'Hare T; Lee KA; Corbin AS; Stoffregen EP; Smith C; Johnson K; Moseson EM; Wood LJ; Polakiewicz RD; Druker BJ; Deininger MW
    Mol Cell Biol; 2006 Aug; 26(16):6082-93. PubMed ID: 16880519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of BCR-ABL mutations and resistance to imatinib mesylate.
    Branford S; Hughes T
    Methods Mol Med; 2006; 125():93-106. PubMed ID: 16502579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
    O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
    Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O
    Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
    Kurzrock R; Kantarjian HM; Druker BJ; Talpaz M
    Ann Intern Med; 2003 May; 138(10):819-30. PubMed ID: 12755554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL.
    Beissert T; Hundertmark A; Kaburova V; Travaglini L; Mian AA; Nervi C; Ruthardt M
    Int J Cancer; 2008 Jun; 122(12):2744-52. PubMed ID: 18366061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.